跳至主要内容
临床试验/NCT06900738
NCT06900738尚未招募不适用

A Study to Evaluate Non-invasive Measurements of the Inflammatory Status in Patients with IBD

Universitaire Ziekenhuizen KU Leuven1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
50
试验地点
1
主要终点
Correlation of the the PPG signal with any dynamic biomarker

研究概览

简要总结

Patients with IBD, including both Crohn's disease and ulcerative colitis, require accurate monitoring of intestinal inflammation for optimal follow-up and treatment. Traditional markers like C-reactive protein (CRP) and faecal calprotectin are useful but are either invasive or disliked by patients and a proper continuous monitoring is not feasible with fragmented biomarker information.

The NimBio technology provides support for the clinicians who are managing IBD patients' care based on a wearable technology that allows tracking responsiveness of blood flow properties (also called hemorheology) to inflammatory processes. NimBio's technology analyses blood flow properties using photoplethysmography (PPG), an optical signal, which detects blood flow changes in the microvascular bed of tissues. The PPG signal is obtained from a commercially available wearable (bracelet) which is convenient for the patients. Based on the impact of inflammation on parameters influencing hemorheology (mainly blood vessel stiffness, blood viscosity and red blood cell aggregation) and the fact that the PPG signal mirrors blood flow characteristics, PPG measurements are associated with changes in inflammatory biomarkers and therefore correlate with disease activity.

This offers a possibility for continuous, non-invasive monitoring of inflammation. The study aims to further validate the NimBio Inflammometer and its value for monitoring inflammatory changes and dynamics in patients with IBD at the University Hospitals Leuven.

详细描述

Patients with IBD, including both Crohn's disease and ulcerative colitis, require accurate monitoring of intestinal inflammation for optimal follow-up and treatment. Traditional markers like C-reactive protein (CRP) and faecal calprotectin are useful but are either invasive or disliked by patients and a proper continuous monitoring is not feasible with fragmented biomarker information.

The NimBio technology provides support for the clinicians who are managing IBD patients' care based on a wearable technology that allows tracking responsiveness of blood flow properties (also called hemorheology) to inflammatory processes. NimBio's technology analyses blood flow properties using photoplethysmography (PPG), an optical signal, which detects blood flow changes in the microvascular bed of tissues. The PPG signal is obtained from a commercially available wearable (bracelet) which is convenient for the patients. Based on the impact of inflammation on parameters influencing hemorheology (mainly blood vessel stiffness, blood viscosity and red blood cell aggregation) and the fact that the PPG signal mirrors blood flow characteristics, PPG measurements are associated with changes in inflammatory biomarkers and therefore correlate with disease activity.

This offers a possibility for continuous, non-invasive monitoring of inflammation. The study aims to further validate the NimBio Inflammometer and its value for monitoring inflammatory changes and dynamics in patients with IBD at the University Hospitals Leuven

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • •At least 18 years of age at the time of signing the Informed Consent Form (ICF)
  • •Diagnosis of IBD (Crohn's disease or ulcerative colitis) or IBDU
  • •Hospitalized or ambulatory patients with active IBD defined as:
  • •HBI ≥ 5, or PMS score ≥3, and
  • •Faecal Calprotectin ≥200 μg/g or CRP > 10 mg/ml, and
  • •Access to iOS or Android-based smartphone with internet access
  • •Ambulatory patients would be recruited to the study with a gender ratio that will not deviate from a 40:60 ratio in favor of either gender

排除标准

  • •Allergy to steel or elastomer/rubber
  • •Using a pacemaker, implantable cardiac defibrillator, neurostimulator, or other electronic medical equipment

研究组 & 干预措施

IBD patients with inflammometer

Other

blood samples, stool samples, questionnaires and inflammometer measurements

干预措施: Inflammometer (Device)

结局指标

主要结局

Correlation of the the PPG signal with any dynamic biomarker

时间窗: 6 months

Correlation of the inflammatory dynamics (trajectory) as measured by NimBio's technology with any dynamic biomarker in the IBD patient population

次要结局

  • Correlation of the PPG signal with the patient inflammatory status(6 months)
  • Classification of the inflammatory status based on the PPG signal(6 months)
  • Correlation of the inflammatory trajectory with the patient's inflammatory status(6 months)
  • Classification of the inflammatory status compared to the clinical disease activity(6 months)
  • Time of NimBio's indication of a change in the inflammatory status(6 months)
  • Assessment of physiological parameters(6 months)
  • Assessment of patient satisfaction(6 months)
  • Assessment of the correlation between the inflammatory status and disease activity(6 months)
  • The effect of the integration of physiological parameters into NimBio's algorithm(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marc Ferrante

Prof. dr. Marc Ferrante

Universitaire Ziekenhuizen KU Leuven

研究点 (1)

Loading locations...

相似试验